Breast Cancer Risk Reduction and Counseling: Lifestyle, Chemoprevention, and Surgery

Qualitative and quantitative approaches to risk assessment are useful for identifying women at increased risk for developing breast cancer for whom genetics consultation, individualized surveillance recommendations, or chemoprevention may be appropriate. A comprehensive medical and family history review can be used to stratify women into categories of breast cancer risk. A quantitative estimate of the probability of developing breast cancer can be determined using risk assessment tools, such as the Gail and Claus models. Women at increased risk for breast cancer may benefit from individualized approaches to breast cancer risk reduction. Prevention strategies for reducing breast cancer risk include lifestyle modifications, chemoprevention, surgical approaches, and pharmacotherapy.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute - Carlton 307, Elm and Carlton Streets, Buffalo, NY 14263. E-mail: Martin.Mahoney@RoswellPark.org
  • 1.

    American Cancer Society. Cancer Facts & Figures 2007. Available at: http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp. Accessed July 19 2007.

    • Search Google Scholar
    • Export Citation
  • 2.

    Surveillance, Epidemiology, and End Results (SEER) Program. DevCan database: SEER 17 Incidence and Mortality 2000–2003. National Cancer InstituteDCCPS Surveillance Research Program Cancer Statistics Branch. Available at: http://www.seer.cancer.gov. Accessed July 19 2007.

    • Search Google Scholar
    • Export Citation
  • 3.

    SingletarySE. Rating the risk factors for breast cancer. Ann Surg2003;237:474482.

  • 4.

    Levy-LahadEFriedmanE. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer2007;96:1115.

  • 5.

    WhittemoreASGongGJohnEM. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev2004;13:20782083.

    • Search Google Scholar
    • Export Citation
  • 6.

    MaloneKEDalingJRDoodyDR. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black american women ages 35 to 64 years. Cancer Res2006;66:82978308.

    • Search Google Scholar
    • Export Citation
  • 7.

    BhatiaSRobisonLLOberlinO. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med1996;334:745751.

  • 8.

    HancockSLTuckerMAHoppeRT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst1993;85:2531.

  • 9.

    TravisLBHillDADoresGM. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA2003;290:465475.

    • Search Google Scholar
    • Export Citation
  • 10.

    Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood adolescent and young adult cancers version 2. Available at: http://www.survivorshipguidelines.org/. Accessed July 19 2007.

    • Search Google Scholar
    • Export Citation
  • 11.

    SaslowDBoetesCBurkeW. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin2007;57:7589.

    • Search Google Scholar
    • Export Citation
  • 12.

    GailMHBrintonLAByarDP. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst1989;81:18791886.

    • Search Google Scholar
    • Export Citation
  • 13.

    ClausEBRischNThompsonWD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet1991;48:232242.

  • 14.

    van AsperenCJJonkerMAJacobiCE. Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomarkers Prev2004;13:8793.

    • Search Google Scholar
    • Export Citation
  • 15.

    ClausEBRischNThompsonWD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer1994;73:643651.

    • Search Google Scholar
    • Export Citation
  • 16.

    ClausEBRischNThompsonWD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat1993;28:115120.

    • Search Google Scholar
    • Export Citation
  • 17.

    ParmigianiGBerryDAguilarO. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet1998;62:145158.

    • Search Google Scholar
    • Export Citation
  • 18.

    ChenJPeeDAyyagariR. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst2006;98:12151226.

    • Search Google Scholar
    • Export Citation
  • 19.

    BarlowWEWhiteEBallard-BarbashR. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst2006;98:12041214.

    • Search Google Scholar
    • Export Citation
  • 20.

    RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA2002;288:321333.

  • 21.

    RossRKPaganini-HillAWanPCPikeMC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst2000;92:328332.

    • Search Google Scholar
    • Export Citation
  • 22.

    FisherBCostantinoJPWickerhamDL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst1998;90:13711388.

    • Search Google Scholar
    • Export Citation
  • 23.

    VogelVGCostantinoJPWickerhamDL. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA2006;295:27272741.

    • Search Google Scholar
    • Export Citation
  • 24.

    CauleyJANortonLLippmanME. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat2001;65:125134.

    • Search Google Scholar
    • Export Citation
  • 25.

    MartinoSCauleyJABarrett-ConnorE. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst2004;96:17511761.

    • Search Google Scholar
    • Export Citation
  • 26.

    Barrett-ConnorEMoscaLCollinsP. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med2006;355:125137.

    • Search Google Scholar
    • Export Citation
  • 27.

    FisherBCostantinoJPWickerhamDL. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst2005;97:16521662.

    • Search Google Scholar
    • Export Citation
  • 28.

    EttingerBBlackDMMitlakBH. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA1999;282:637645.

    • Search Google Scholar
    • Export Citation
  • 29.

    DelmasPDBjarnasonNHMitlakBH. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med1997;337:16411647.

    • Search Google Scholar
    • Export Citation
  • 30.

    CummingsSREckertSKruegerKA. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA1999;281:21892197.

    • Search Google Scholar
    • Export Citation
  • 31.

    BeversTB. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother2006;7:23012307.

  • 32.

    ArmstrongKQuistbergDAMiccoE. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med2006;166:22602265.

    • Search Google Scholar
    • Export Citation
  • 33.

    BeversTBArmstrongDKArunB. NCCN breast cancer risk reduction clinical practice guidelines in oncology version 12007. Available athttp://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Last accessed 1 June 2007.

    • Search Google Scholar
    • Export Citation
  • 34.

    CoombesRCHallEGibsonLJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004;350:10811092.

    • Search Google Scholar
    • Export Citation
  • 35.

    GossPEIngleJNMartinoS. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med2003;349:17931802.

    • Search Google Scholar
    • Export Citation
  • 36.

    BaumMBudzarAUCuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet2002;359:21312139.

    • Search Google Scholar
    • Export Citation
  • 37.

    MoormanPGGrubberJMMillikanRCNewmanB. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control2003;14:915922.

    • Search Google Scholar
    • Export Citation
  • 38.

    SwedeHMirandALMenezesRJMoysichKB. Association of regular aspirin use and breast cancer risk. Oncology2005;68:4047.

  • 39.

    CookNRLeeIMGazianoJM. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA2005;294:4755.

    • Search Google Scholar
    • Export Citation
  • 40.

    HartmannLCSchaidDJWoodsJE. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med1999;340:7784.

    • Search Google Scholar
    • Export Citation
  • 41.

    HartmannLCSellersTASchaidDJ. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst2001;93:16331637.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 77 67 4
PDF Downloads 54 52 3
EPUB Downloads 0 0 0